HUIZENGA THEODORE ALAN (SVP, Chief Accounting Officer) sold 8.4% of their position (2.16K shares) of ULTRAGENYX PHARMACEUTICAL INC. on the open market
Open‑market sale worth $88.2K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 9/11/2023ACC: 0001209191-23-048905
Officer· SVP, Chief Accounting Officer
Since Mar 2026
-2.16K
Net shares
Net seller
$88.2K
Total sold
2
Open market trades
0B · 2S
4
Total transactions
2K acquired · 4.16K disposed
Non-Derivative Transactions3
Common Stock
Direct
Shares
+2K
Price / share
$21.00
Trade value
$42K
% of position
8.4%
9/7/2023
23.78K→25.78K
Common Stock
Direct
Shares
−2K
Price / share
$41.00
Trade value
$82K
% of position
7.8%
9/7/2023
25.78K→23.78K
Common Stock
Direct
Shares
−163.00
Price / share
$38.34
Trade value
$6.25K
% of position
0.7%
9/7/2023
23.78K→23.61K
Total
Net shares
−163.00
Net value
-$46.25K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 9/7/2023 | M · Option Exercise | +2K | $21.00 | $42K | 8.4% | 23.78K | 25.78K |
| Common Stock Direct | 9/7/2023 | S · Sale | −2K | $41.00 | $82K | 7.8% | 25.78K | 23.78K |
| Common Stock Direct | 9/7/2023 | S · Sale | −163.00 | $38.34 | $6.25K | 0.7% | 23.78K | 23.61K |
| Total | −163.00 | -$46.25K | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
2K shares
Shares
−2K
Strike price
21.00
Held after
3K
Exercisable
—
9/7/2023
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock2K shares | 9/7/2023 | M · Option Exercise | −2K | 21.00 | — | 3K |